Media stories about Co-Diagnostics (NASDAQ:CODX) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Co-Diagnostics earned a daily sentiment score of 0.04 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.6853785900783 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Shares of CODX traded down $0.22 during midday trading on Monday, hitting $1.86. The company’s stock had a trading volume of 38,392 shares, compared to its average volume of 37,754. Co-Diagnostics has a one year low of $1.45 and a one year high of $6.85.
ILLEGAL ACTIVITY NOTICE: “Co-Diagnostics (CODX) Receives Daily Media Sentiment Rating of 0.04” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/04/09/co-diagnostics-codx-receives-daily-media-sentiment-rating-of-0-04.html.
Co-Diagnostics, Inc, a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also sells diagnostic equipment from other manufacturers as self-contained lab systems. The company develops DNA-based testing platform, for the detection of disease, genetic disorders, and other conditions.
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.